The FDA has approved Novartis’ Fabhalta (iptacopan) as the first and only treatment for C3 glomerulopathy (C3G). Previously, patients with C3G were forced to rely on supportive care and broad ...
Increased testing for Rh and Kell phenotypes could reduce the risk of adverse transfusion reactions and HDFN, a study found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback